Global Respiratory Syncytial Virus (RSV) Therapeutics Market- Snapshot
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. A RSV infection can lead to serious problems such as bronchiolitis and pneumonia. In terms of revenue, the global respiratory syncytial virus (RSV) therapeutics market was valued at US$ 841.4 Mn in 2016 and is anticipated to reach more than US$ 2100.0 Mn by 2025, expanding at a CAGR of 11.7% from 2017 to 2025.

Source: Click here

Share this article

Facebook Comments